Related Experiment Videos
Three novel single nucleotide polymorphisms in UGT1A9
Mayumi Saeki1, Yoshiro Saito, Hideto Jinno
1Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan.
Drug Metabolism and Pharmacokinetics
|December 25, 2004
Summary
Researchers identified three novel single nucleotide polymorphisms (SNPs) in the UDP-glucuronosyltransferase (UGT) 1A9 gene in Japanese individuals. These UGT1A9 gene variations include one that creates a premature stop codon and two synonymous changes.
Area of Science:
- Genetics
- Pharmacogenomics
Background:
- The UDP-glucuronosyltransferase (UGT) 1A9 enzyme plays a crucial role in drug metabolism and detoxification.
- Genetic variations in UGT genes can influence drug efficacy and toxicity.
- Understanding UGT1A9 polymorphisms is important for personalized medicine.
Purpose of the Study:
- To identify novel single nucleotide polymorphisms (SNPs) in the UGT1A9 gene.
- To investigate the frequency and potential functional impact of these SNPs in a Japanese population.
Main Methods:
- DNA sequencing of the UGT1A9 gene in 97 Japanese subjects (47 cancer patients, 50 cardiovascular disease patients).
- Identification and characterization of novel SNPs.
- Analysis of SNP locations within the gene and their predicted effects on protein sequence.
Main Results:
- Three novel SNPs were identified in exon 1 of the UGT1A9 gene.
- SNP MPJ6_U1A007 (726T>G) results in a premature termination codon (Y242X).
- SNPs MPJ6_U1A006 (588G>T) and MPJ6_U1A031 (153G>A) are synonymous variants (G196G and R51R, respectively).
Conclusions:
- Novel UGT1A9 SNPs have been discovered in the Japanese population.
- One identified SNP has a significant functional consequence, potentially affecting protein function.
- Further research is warranted to explore the clinical implications of these UGT1A9 genetic variations.